Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News today November 27th 2023:
InnovaQor, Inc. (INQR) authorizes two new series of preferred stock, Series E and Series F, for potential exchange offer to common shareholders. The Series E Mandatory Convertible Preferred Stock has a mandatory conversion date of December 31, 2026, and the Series F Mandatory Convertible Preferred Stock has a mandatory conversion date of December 31, 2027. The stated value of each series of preferred stock initially is $100, increasing by $20 upon each anniversary of issuance. The exchange offer is being considered as an alternative to completing a reverse split of common stock to attract new investors. The terms and timing of the exchange offer are subject to final approval by the Board of Directors and market conditions.
This is what I wrote a while ago (see Intro) about Curallo:
InnovaQor is a kind of a pioneer in the domain of creating a social platform for physicians, creating a networking, knowledge sharing, and hiring mechanism along the lines of LinkedIn. There is a global shortfall of 4.3 million doctors, nurses, and other healthcare professionals. Through its platform Curallo.com, INQR primarily targets physician groups, facilities and associations trying to acquire advocacy through the larger governing boards with a member-exclusive discount.
The revenue streams of this social media platform would include freemium, premium subscription fees, sponsorship, talent search per individual/ facility, and so on. As LinkedIn has shown, there is a need for additional access, knowledge, and connectivity, which comes with a monthly premium access fee. In fact, LinkedIn’s data indicates that individuals are willing to spend $30, while corporations are willing to pay $60 for such services which means INQR definitely can earn strong revenues from its niche.
The Talent Search Subscription Program (TSSP) is anticipated to upend the market by utilizing AI for matchmaking based on user profile optimization. The TSSP feature on LinkedIn generates 65% of the company's revenue, displacing market leaders like Monster and Indeed. With INQR/Curallo employing an industry-specific model, TSSP is a boon for healthcare professionals, especially in todays hiring market. Large pharma would find the platform to be alluring for advertising with an engaged industry audience as well. Thus, this new platform could be a huge revenue catalyst for INQR.
From what I heard the curallo MVP is complete. The outside funding that INQR needs is tied to the MVP. Not only does INQR need 2.5 million dollar to repay former parent Rennova, but they also need cash to further develop the healthcare modules. Before this year ends INQR has to repay RNVA's promissory note receivable and therefore I expect news very soon.
no one will fund this lame disaster. "outside partner" these clowns have no help they left themselves out to dry. this is indebted, no asset having broke trash stock is worthless no one wants anything to do with it
CURALLO? The company is not even able to realize the announced minimum viable product (MVP) to demonstrate their platform. LOL
Quote:
InnovaQor is building a Minimum Viable Product (MVP) to demonstrate our platform. This part of our project should be complete by the end of September 2023.
https://curallo.com/status/
The quarterly financials were filed yesterday. No big surprises, BUT former parent Rennova is pouring in more loans to enable InnovaQor to develop their Medical Professionals Communication Platform called CURALLO. In total loans from Related parties (Rennova) add up to $2,466,085. A while ago the CEO of Rennova said in an interview that he expects to get it all repaid as soon as Innovaqor gets fully funded from an outside partner. That funding is expected as/when the Curallo peer-to-peer communication module is ready and accepted. I'm expecting news any moment now.
SEC Filing Alert
NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
I stand by it, as long as this Gerard Dab continues to have his fingers in the game, nothing will come of this stock. A pity!
if this ever gets a fair run i take it all back and apologize to management until then.... the offerings. the PRs. the constant change in "ceo". name change. audited/state filings. yet the impending dilution, the lack of communication, no one seems to care. so far so flop
for a low float l2 sure is thick. what a waste
watch this disaster sink in to oblivion. what a loser stock run by incompetent scum
1 million wall at 005 no one touches it. no one wants this disaster . Huge dilution. Peterson is also director of another otc ticker which is highly sus .
I was a big fan of Innovaqor, looked very solid, but I have my doubts now. Seems the new CEO is a jerk, not explaining what’s going on. Why all recent filings with the SEC, new management and so on? Innovaqor has become a typical Pink Sheets company. Pity
900 at 005 what happened !?! such garbage trash ! dab, peterson are garbage this stock is screwed !!
Credibility is ZERO. The company's announcements still cannot be trusted.
Quote:
InnovaQor is building a Minimum Viable Product (MVP) to demonstrate our platform. This part of our project should be complete by the end of September 2023.
https://curallo.com/status/
LOL dang sorry I asked I didn't mean to rattle the cages. thanks for your opinion I have been here in pinks for some time and know the drill. and the risk.
because it is a trash scam nothing but debt, offerings, and dilution here . management is a bunch of buffoons they got the 3 stooges running things over there
Just look at the finances of the last years, then you can answer the question yourself. More or less only expenses and virtually no income. As long as this does not change, interest in the share will certainly remain limited.
I'll slowly accumulate and wait. RNVA has a plan \.
why isn't anyone buying or selling this stock? new here tia
Quote: InnovaQor is building a Minimum Viable Product (MVP) to demonstrate our platform. This part of our project should be complete by the end of September 2023.
https://curallo.com/status/
started a position this morning I like the Business plan.
All efforts (and funds) are invested in the new Medical Professional Communication Platform. The existing healthcare modules that are on the market (medicalmime EHR, Clinlab, Qira etc) will be (a small) part of the new Curallo:
https://curallo.com
It was realy a bulshit interview, but curallo does excist @EHR Junkie
It was realy a bulshit interview, but curallo does excist @EHR Junkie
one of the worst stocks ever. peterson dab lol clown show. nothing but offerings and dilution just a sad sad pathetic waste of ticker . that stupid stockday and his worthless interviews does not help
your guess is as good as mine, all costs financed by former parent company
When does the company actually intend to make some money? At the moment, it seems as if the company only serves to finance the immensely high administrative costs (on credit).
this company puts out so many filings and pr news yet goes no where. now today a nt 10q great no
If you're a shareholder you should do some DD and you'd know their future is Curallo
there is no such thing as curallo this yahoo is making crap up on this board !! what is going on here who is this clown !!
Can't tell, but before I post anything I always double check. I tried to explain that Innovaqor's future is based on the Curallo platform, the media & communication platform that is a networking, knowledge sharing, and hiring mechanism. The healthcare modules (Medical Mime etcetera) that Innovaqor is marketing/selling at the moment will be part of Curallo.
In the US there is a global shortfall of some 4.3 million doctors, nurses, and other healthcare professionals. Through its platform Innovaqor primarily targets physician groups, facilities and associations trying to acquire advocacy through the larger governing boards with a member-exclusive discount. Competitors are LinkedIn, MonsterBoard etcetera, but Innovaqor is specifically targeting the healthcare sector. Innovaqor expects blow out revenue from Curallo. The dividend scheme for holders of the series D preferred stock (see Form 8-K/A from 05/19/23) is solely based on revenue projections from Curallo.
But do your own DD. Good luck
I know they secured major funding from an outside source and it has to be announced shortly. I'm not sure about something else: did they find a partner to launch Curallo? I think they did and the recently filed Form 8-K (from 07/06/23) to raise the A/S to 2B shares could point to that.
May we know where you find this “Curallo” information. Link? Thanks.
I know expectations here are very low, but I did some research. The media & communication platform (Curallo) is being build in Montreal. They started building in the second quarter 2023. A first version should be ready by now. If you take a look at the Q1-financials you know they didn't have any cash to invest. So where did the cash to invest in Curallo come from? Just connect the dots. Gerard Dab received a $60,000 bonus (paid out in Q2) for securing funding and that's big news. This stock will move north very soon, believe me.
$INQR Innovaqor inc.
*) The IP is currently worth more than the company's Market Cap,
*) Healthcare Technology Solutions, InnovaQor's IT Services business is in place and booking revenues,
*) Federal Initiatives to curb opioid abuse will fund outreach initiatives to bring patients into care environments specifically tailored to Opiate and Alcohol abuse and recovery,
*) InnovaQor has invested $20m and currently is used in Healthcare Institutions with Critical necessity designation by the Federal government,
*) InnovaQor has an EMR offering that will expand the capability to assess and address Clinical Opiate Withdrawal. Opiate abuse recovery is a major driver in Healthcare costs. Full lifecycle management with predictive analytics and decision support,
*) Innovaqor is developing a media and communication platform (Curallo) for healthcare professionals. Part of it will be a networking, knowledge sharing, and hiring mechanism (Talent Search) along the lines of LinkedIn and MonsterBoard, revenue streams would include freemium, premium subscription fees, sponsorship, talent search per individual/ facility etcetera
*) Innovaqor's Talent Search Subscription Program (TSSP) is anticipated to upend the market by utilizing AI for matchmaking based on user profile optimization. With InnovaQor employing an industry-specific model, TSSP is a boon for healthcare professionals, especially in todays hiring market. Large pharma would find the platform to be alluring for advertising with an engaged industry audience as well. Thus, this new platform could be s huge revenue catalyst for InnovaQor.
[b]In my opinion Innovaqor is vastly undervalued. Let's see what happens when they start talking. And mind you, CURALLO (the communication platform) is what it's all about!!!)
they keep selling stock these offerings never end. this isnt going anywhere for a long time if at all. total failure here
$INQR
"Our goal is to develop and deliver a technology-based network communication platform to a broad range of healthcare professionals and businesses using a subscription revenue model with added value bolt on services. The Company has initiated this project in the second quarter of 2023 and is working with a Canadian-based development company to create a minimum viable product (MVP) to demonstrate the peer-to-peer communication capabilities. The Company will launch this new platform under the name Curallo.
The Company believes the current solutions will become an added value option to a technology-based network communication platform (Curallo) to a broad range of healthcare professionals and businesses using a subscription revenue model with added value bolt on services the Company plans to develop."
In my humble opinion: Curallo will be the new business. All existing solutions that INQR offers today will be added to the communication platform. Sounds good to me. If you take the trouble to read all recent filings, you will agree with me that they have new funding. Hollis got her loan repaid, Dab received a 60K bonus and they have the money to start building a totally new communication platform. Also former parent company Rennova expects to get their loans to INQR repaid shortly. Wait till they start talking. I'm expecting a PR any day now. Good luck
Het is moeilijk voor te stellen dat het tij ten goede keert zolang deze Gerard Dab zijn vingers in de taart houdt.
Wat is dan de koers verwachting want door Gerard Dab zijn we jaren lang voorgelogen en bedonderd.
$INQR A few months ago the CEO of Rennova Health (former parent company of Innovaqor) gave an interview to MoneyTV. I'm not a fan of Seamus Lagan, but listen to the interview, the INQR-part starts at 5:25
In the interview he also says that INQR will get funding and they're able to pay back the loans to Rennova very soon. And that was a few months ago!
$INQR what happened recently:
1) new management team (Sharon Hollis out, Darrell Peterson new CEO)
2) changes in B.O.D.
3) funding is in place (Gerard Dab was paid 60K in Q2 2023)
4) A/S was raised to 2B shares from 350M
5) working on a Medical Professional Communication Platform for Healthcare Providers (using a subscription revenue model)
6) 3 founders (Seamus Lagan, Sharon Hollis, Justin Doherty) received series D preferred stock
7) that series D entitles them to dividend based on the monthly revenue (5% in excess of 500K, 10% above 1,000K and 2.5% above 2,500K
8) it's all happening and we're very close
Shares will go to big investor, see the 10Q, the part where it says G. Dab received 60K for bringing in funding. As far as I know things are moving in the right direction. Funding in place, new MT and BOD, revenue stream coming (see 8-K/A) and probably news about communication platform for healthcare providers (in development). Let's see what happens, after filing the 8-K about increase of A/S they should start talking
At least the stuff won't taste so salty anymore. Joking aside - the company needs fresh capital to invest. Well invested, it brings in many times more.
great theyre gonna dilute the piss out of it wonderful
the number authorised shares increased to 2 billion
On June 29 and June 30 new amendments filed (Nevada SOS):
- new board members (Darrell Peterson CEO) and (Francisco Rocca Director)
- A/S raised from 350M to 2,000M
My humble opinion: they have secured funding
got the ball rolling flying low under the radar could easily take otc by surprise
These guys are slow updating shareholders and others, incredible! Changes in management team and BOD indicate there's a lot happening behind the curtain. The dividend agreement (see latest form 8K/A) for the 3 founders tells me they expect rapidly increasing revenues, maybe they signed up a few big partner. Something's happening here.........
InnovaQor is a kind of a pioneer in the domain of creating a social platform for physicians, creating a networking, knowledge sharing, and hiring mechanism along the lines of LinkedIn. There is a global shortfall of 4.3 million doctors, nurses, and other healthcare professionals. Through its platform Curallo.com, InnovaQor primarily targets physician groups, facilities and associations trying to acquire advocacy through the larger governing boards with a member-exclusive discount. The revenue streams of this social media platform would include freemium, premium subscription fees, sponsorship, talent search per individual/ facility, and so on. As LinkedIn has shown, there is a need for additional access, knowledge, and connectivity, which comes with a monthly premium access fee. In fact, LinkedIn’s data indicates that individuals are willing to spend $30, while corporations are willing to pay $60 for such services which means InnovaQor definitely can earn strong revenues from its niche. The Talent Search Subscription program is anticipated to upend the market by utilizing AI for matchmaking based on user profile optimization. The Talent Solutions feature on LinkedIn generates 65% of the company's revenue, displacing market leaders like Monster and Indeed. With InnovaQor/Curallo employing an industry-specific model, TSSP is a boon for healthcare professionals, especailly in todays hiring market. Large pharma would find the platform to be alluring for advertising with an engaged industry audience as well. Thus, this new platform could be a huge revenue catalyst for InnovaQor.
ClinLab is a proprietary Windows-based, Internet and web-enabled laboratory information management system. Designed by medical technologists, ClinLab is scalable from small point-of-care labs to large multi-user, multi-location clinical facilities. ClinLab acts as a data warehouse for lab results and includes reporting, data acquisition, label printing, electronic signoff and provides numerous interface capabilities to a multitude of reference labs and practice systems.
Healthcare Technology Solutions (HTS) Virtual Chief Information Officer (vCIO) services provides one-stop, specialized IT services for healthcare facilities which enhance business operations and encourage sustainable growth. Our services focus on infrastructure-related management and we ensure you maintain a competitive advantage with innovative technology solutions. With HTS's vCIO services, organizations gain access to best-in-class managed IT and cloud solutions without the headaches of supporting an in-house staff.
Qira analytics integrates data across your entire business – streamlining operations that improve services, reporting and financial health.
MEDtuning delivers Personalized Medicine to modern clinical practices. MEDtuning develops revolutionary PhyzioType Systems for DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease, and diabetes. These systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance.
WEST PALM BEACH, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- InnovaQor, Inc. (OTC: VMCS), today announced that it became a fully SEC reporting company on September 27, 2022 when its Form 10-12G that was filed on September 7, 2022 became effective.
For more information:
https://www.innovaqor.com/
https://medicalmime.com/
https://healthtechnologysolutions.com/analytics/
https://healthtechnologysolutions.com/vcio-services/
https://clinlabinc.com/
https://www.otcmarkets.com/stock/VMCS/security
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |